Uncategorized

Dyne Therapeutics, Inc., a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, announced it now plans to report new efficacy and safety data from its Phase 1/2 ACHIEVE and DELIVER clinical trials on May 20, 2024, and to host a virtual event at 8:00 a.m. ET.

Endeavor BioMedicines announced results from a completed Phase 2a clinical trial that demonstrate the company’s lead investigational candidate, ENV-101, improved lung function and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis over a 12-week period.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society 2024 International Conference that is taking place May 17-22, 2024, in San Diego, CA.

bioLytical Laboratories Inc., a global leader in rapid diagnostic tests, proudly announces the immediate availability of its INSTI® HCV Antibody Test in the Australian market.

Virios Therapeutics, Inc. announced the pricing of its previously announced public offering of 8,500,000 shares of its common stock at a public offering price of $0.20 per share.

The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease with a broad range of blood eosinophil counts and irrespective of emphysema, chronic bronchitis or smoking status.

Zai Lab Limited and Innoviva Specialty Therapeutics announced that China’s National Medical Products Administration has approved Zai Lab’s New Drug Application for XACDURO® for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older.

Innovent Biologics, Inc. announces that the company will deliver oral presentations on clinical data of its first-in-class PD-1/IL-2 bispecific antibody fusion protein and novel Topoi anti-Claudin18.2 ADC at the upcoming medical conferences in June, including ESMO Virtual Plenary and ESMO Gastrointestinal Cancers Congress 2024.

Life science companies can protect intellectual property in multiple ways, including leveraging IP rights.

Una nueva era de procesamiento de datos y de ayudas para la clínica que requiere una integración armoniosa